Targeting Ribosomal Frameshifting as an Antiviral Strategy: From HIV-1 to SARS-CoV-2

Author(s):  
Viktoriya S. Anokhina ◽  
Benjamin L. Miller
2010 ◽  
Vol 285 (26) ◽  
pp. 19776-19784 ◽  
Author(s):  
Yoshifumi Kobayashi ◽  
Jianling Zhuang ◽  
Stuart Peltz ◽  
Joseph Dougherty

Viruses ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 54 ◽  
Author(s):  
Fu-Hsien Yu ◽  
Kuo-Jung Huang ◽  
Chin-Tien Wang

The pol retrovirus gene encodes required enzymes for virus replication and maturation. Unlike HIV-1 Pol (expressed as a Gag–Pol fusion protein), foamy virus (described as an ancient retrovirus) expresses Pol without forming Gag–Pol polyproteins. We placed a “self-cleaving” 2A peptide between HIV-1 Gag and Pol. This construct, designated G2AP, is capable of producing virions with the same density as a wild-type (wt) HIV-1 particle. The 2A peptide allows for Pol to be packaged into virions independently from Gag following co-translationally cleaved from Gag. We found that G2AP exhibited only one-third the virus infectivity of the wt, likely due, at least in part, to defects in Pol packaging. Attenuated protease (PR) activity, or a reduction in Pol expression due to the placement of 2A-mediated Pol in a normal Gag–Pol frameshift context, resulted in significant increases in virus yields and/or titers. This suggests that reduced G2AP virus yields were largely due to increased PR activity associated with overexpressed Pol. Our data suggest that HIV-1 adopts a gag/pol ribosomal frameshifting mechanism to support virus assembly via the efficient modulation of Gag–Pol/Gag expression, as well as to promote viral enzyme packaging. Our results help clarify the molecular basis of HIV-1 gene expression and assembly.


2006 ◽  
Vol 119 (1) ◽  
pp. 29-42 ◽  
Author(s):  
Ian Brierley ◽  
Francisco J. Dos Ramos

2004 ◽  
Vol 78 (4) ◽  
pp. 2082-2087 ◽  
Author(s):  
Preetha Biswas ◽  
Xi Jiang ◽  
Annmarie L. Pacchia ◽  
Joseph P. Dougherty ◽  
Stuart W. Peltz

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) utilizes a distinctive form of gene regulation as part of its life cycle, termed programmed −1 ribosomal frameshifting, to produce the required ratio of the Gag and Gag-Pol polyproteins. We carried out a sequence comparison of 1,000 HIV-1 sequences at the slippery site (UUUUUUA) and found that the site is invariant, which is somewhat surprising for a virus known for its variability. This prompted us to prepare a series of mutations to examine their effect upon frameshifting and viral infectivity. Among the series of mutations were changes of the HIV-1 slippery site to those effectively utilized by other viruses, because such mutations would be anticipated to have a relatively mild effect upon frameshifting. The results demonstrate that any change to the slippery site reduced frameshifting levels and also dramatically inhibited infectivity. Because ribosomal frameshifting is essential for HIV-1 replication and it is surprisingly resistant to mutation, modulation of HIV-1 frameshifting efficiency potentially represents an important target for the development of novel antiviral therapeutics.


Nature ◽  
1988 ◽  
Vol 331 (6153) ◽  
pp. 280-283 ◽  
Author(s):  
Tyler Jacks ◽  
Michael D. Power ◽  
Frank R. Masiarz ◽  
Paul A. Luciw ◽  
Philip J. Barr ◽  
...  

Cell ◽  
2019 ◽  
Vol 176 (3) ◽  
pp. 625-635.e14 ◽  
Author(s):  
Xinlu Wang ◽  
Yifang Xuan ◽  
Yuling Han ◽  
Xiang Ding ◽  
Kai Ye ◽  
...  

RNA ◽  
2014 ◽  
Vol 20 (5) ◽  
pp. 587-593 ◽  
Author(s):  
Xiaolan Huang ◽  
Yang Yang ◽  
Guan Wang ◽  
Qiang Cheng ◽  
Zhihua Du

2021 ◽  
Author(s):  
Bayleigh E. Benner ◽  
James W. Bruce ◽  
Jacob R. Kentala ◽  
Magdalena Murray ◽  
Jordan T. Becker ◽  
...  

HIV-1 virion production is driven by Gag and Gag-Pol (GP) proteins, with Gag forming the bulk of the capsid and driving budding while GP binds Gag to deliver the essential virion enzymes Protease, Reverse Transcriptase, and Integrase. Virion GP levels are traditionally thought to reflect the relative abundances of GP and Gag in cells (∼1:20), dictated by the frequency of a -1 programmed ribosomal frameshifting (PRF) event occurring in gag-pol mRNAs. Herein we exploited a panel of PRF mutant viruses to show that mechanisms in addition to PRF regulate GP incorporation into virions. First, we show that GP is enriched ∼3-fold in virions relative to cells, with viral infectivity better maintained at subphysiological levels of GP compared to when GP levels are too high. Second, we report that GP is more efficiently incorporated into virions when Gag and GP are synthesized in cis ( i.e., from the same gag-pol mRNA) relative to trans, suggesting that Gag/GP translation and assembly are spatially coupled processes. Third, we show that, surprisingly, virions exhibit a strong upper limit to trans -delivered GP incorporation; an adaptation that appears to allow the virus to temper defects to GP/Gag cleavage that may negatively impact reverse transcription. Taken together, we propose a “weighted Goldilocks” scenario for HIV-1 GP incorporation, wherein combined mechanisms of GP enrichment and exclusion buffer virion infectivity over a broad range of local GP concentrations. These results provide new insights into the HIV-1 virion assembly pathway relevant to the anticipated efficacy of PRF-targeted antiviral strategies. Importance HIV-1 infectivity requires incorporation of the Gag-Pol (GP) precursor polyprotein into virions during the process of virus particle assembly. Mechanisms dictating GP incorporation into assembling virions are poorly defined, with GP levels in virions traditionally thought to solely reflect relative levels of Gag and GP expressed in cells; dictated by the frequency of a -1 programmed ribosomal frameshifting (PRF) event that occurs in gag-pol mRNAs. Herein we provide experimental support for a “weighted Goldilocks” scenario for GP incorporation, wherein the virus exploits both random and non-random mechanisms to buffer infectivity over a wide range of GP expression levels. These mechanistic data are relevant to ongoing efforts to develop antiviral strategies targeting PRF frequency and/or HIV-1 virion maturation.


1998 ◽  
Vol 72 (6) ◽  
pp. 4819-4824 ◽  
Author(s):  
Magdeleine Hung ◽  
Pratiksha Patel ◽  
Susan Davis ◽  
Simon R. Green

ABSTRACT The recent development and use of protease inhibitors have demonstrated the essential role that combination therapy will play in the treatment of individuals infected with the human immunodeficiency virus type 1 (HIV-1). Past clinical experience suggests that due to the appearance of resistant HIV-1 variants, additional therapeutics will be required in the future. To identify new options for combination therapy, it is of paramount importance to pursue novel targets for drug development. Ribosomal frameshifting is one potential target that has not been fully explored. Data presented here demonstrate that small molecules can stimulate frameshifting, leading to an imbalance in the ratio of Gag to Gag-Pol and inhibiting HIV-1 replication at what appears to be the point of viral particle assembly. Thus, we propose that frameshifting represents a new target for the identification of novel anti-HIV-1 therapeutics.


Sign in / Sign up

Export Citation Format

Share Document